[Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia].

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of cefdinir in the treatment of patients with mild to moderate bacterial community acquired pneumonia (CAP).

METHODS:

A prospective single-blind randomized controlled clinical study was performed comparing cefdinir with cefaclor in the treatment of sixty-four patients with CAP. The clinical and bacteriological efficacy and safety were compared between cefdinir and cefaclor in treating mild to moderate CAP. Thirty-three patients were treated with cefdinir 100 mg, orally, three times a day (cefdinir group), thirty-one patients were treated with cefaclor 500 mg, orally, three times a day (cefaclor group). In both groups 7-14 d was a treatment course.

RESULTS:

The cure rate of cefdinir and cefaclor was 84.8% and 77.4% respectively and the overall efficacy rate was 93.9% and 87.1% respectively. The bacterial positive rates and bacterial eradication rates of the two groups were 81.8%, 80.7% and 96.3%, 88%, respectively. The adverse drug reaction rate were 3% in cefdinir group and 6.5% in cefaclor group. There was no statistical significant difference between the two groups for the above results (P >0.05). The time of given medicine of cefdinir and cefaclor was (10.8 +/- 1.6) d and (12.1 +/- 1.7) d (P <0.01) respectively.

CONCLUSION:

cefdinir is safe and effective, shorten the course of treatment in the treatment of mild to moderate bacterial community acquired pneumonia.

• Authors: Xing-tang Jiang, Yan-ping Du, Li-ping Deng
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 84 Issue 22 Pg. 1876-8 (Nov 17 2004) ISSN: 0376-2491 [Print] China
• PMID: 15631797 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• Cefaclor
• Cefdinir

Topics

• Adolescent
• Adult
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Cefaclor (therapeutic use)
• Cefdinir
• Cephalosporins (therapeutic use)
• Community-Acquired Infections (drug therapy, microbiology)
• Humans
• Middle Aged
• Pneumonia, Bacterial (drug therapy, microbiology)
• Prospective Studies
• Single-Blind Method
• Staphylococcal Infections (drug therapy)
• Streptococcal Infections (drug therapy)